Dr. Thompson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-7110
Education & Training
Northwestern UniversityMS, Medical Informatics, 2013 - 2018
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2003- University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2001
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997
Certifications & Licensure
NY State Medical License 2008 - 2026
PA State Medical License 1998 - 2010
American Board of Internal Medicine Hematology
American Board of Preventive Medicine Clinical Informatics
Clinical Trials
- Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 01
Publications & Presentations
PubMed
- Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.Sawyer Bawek, Matthew Burwinkel, Prutha Patel, Katy Wang, Kristopher Attwood
Leukemia Research. 2025-03-01 - Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin
Leukemia & Lymphoma. 2024-12-27 - 12 citationsPivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis
The Lancet. Oncology. 2024-03-01
Abstracts/Posters
- Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) StudyJames E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy BackboneJames E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Buffalo Spree Names Record 143 Roswell Park Physicians as Top Doctors for 2025December 30th, 2024- Roswell Park Licenses Rapid, Comprehensive Blood Test to Agilent, a Global Leader in the Life Sciences MarketOctober 20th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
